Yazar "Gunduz, Eren" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    ASSESSMENT OF CHARACTERISTICS AND TREATMENT PATTERNS OF ADULT PATIENTS WITH ACQUIRED APLASTIC ANAEMIA IN TURKIYE (PLANE-TR STUDY)
    (Springernature, 2025) Gunduz, Eren; Ulas, Turgay; Ozkalemkas, Fahir; Toprak, Selami Kocak; Karakulak, Elifcan Aladag; Ar, Muhlis Cem; Gulbas, Zafer
    [No abstract available]
  • Küçük Resim Yok
    Öğe
    Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR)
    (Springer, 2026) Gunduz, Eren; Ulas, Turgay; Ozkalemkas, Fahir; Toprak, Selami Kocak; Karakulak, Elifcan Aladag; Ar, Muhlis Cem; Gulbas, Zafer
    Acquired aplastic anemia (AA) is a rare blood disorder causing hypocellular bone marrow due to immune damage to hematopoietic stem cells, leading to low blood cell counts. This study investigates the demographics, treatment patterns, and clinical outcomes of AA in Turkiye. In this non-interventional, retrospective descriptive study, data of 274 patients (Female/Male: 4/5) diagnosed with AA between September 1, 2011, and September 1, 2021, were collected from 16 centers. Severe and very severe AA was diagnosed in 72% and 27.7% of patients, respectively. The mean time from diagnosis to first treatment was 119 +/- 287 days, while time to hematopoietic stem cell transplantation (HSCT) was 212 +/- 321 days, and to Anti-Thymocyte Globulin (ATG) was 87 +/- 242.5 days. The mean time to response after first-line and second-line treatment was 172.9 +/- 264.6 days and 191.9 +/- 211.9 days, respectively. The mean overall survival of patients with AA was 3.56 +/- 3.12 years, with a 5-year overall survival rate of 72.6%. HSCT and other initial treatments led to full or partial remission for most patients, improving survival rates for over half of them. The study observed comparable patterns to previous studies, providing vital insights into Turkiye's acquired AA treatment landscape.
  • Küçük Resim
    Öğe
    Retrospective analysis of autologous stem cell transplantation outcomes in multiple myeloma patients with renal insufficiency
    (2021) Goren Sahin, Deniz; Akay, Olga Meltem; Andic, Neslihan; Uskudar Teke, Hava; Gunduz, Eren
    Aim: The most seen complication of multiple myeloma (MM) is renal insufficiency (RI). Although MM is known as one of the causes of reversible end-stage renal disease, these patients are usually not suitable for autologous stem cell transplantation (ASCT). We aimed in this study to reveal the clinical course of MM patients with renal insufficiency that underwent ASCT. Materials and Methods: We included 25 MM patients with RI who has undergone ASCT in this study. Creatinine levels more than 2 mg/dL was defined as renal insufficiency at the time of diagnosis. For survival analysis, we included patients with a minimum 100 days post-transplantation follow-up. Results: Median age was 56.6±7.9 (42-65) years. Melphalan was given 140 mg/m 2 . Nine patients (36%) required dialysis at the time of diagnosis. Six patients became dialysis-free with induction therapy. After ASCT, none of the patients needed dialysis. Cox regression analysis showed a significant increase in disease-free survival (DFS) and overall survival (OS) times compared to patients with very good partial response in patients with complete response on the 100 th day of ASCT (for DFS; 15.7 months vs 63.7 months, p=0.009 and for OS; 37.9 months vs 97.3 months p=0.01, respectively). Conclusion: There are studies showing that ASCT performed with reduced dose of melphalan is a renal protective and effective method in patients with renal impairment. Our study confirms this thesis, as well as emphasizing the significant effect of CR on DFS and OS on the 100 th day after transplantation in these patients.